MWX205 Study Initiated to Assess Safety and Pharmacokinetics in Dyslipidemia Patients
A clinical trial is underway to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MWX205 in patients with dyslipidemia.
Therapeutic Area
Therapeutic area intelligence for Dyslipidemia with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
AstraZeneca is conducting a study to assess the safety, tolerability, PK, and PD of AZD4954 in healthy adults, including those with elevated Lp(a) levels.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.